Pawlyn, C., Kaiser, M. F., Davies, F. E., Morgan, G. J. (2014) Current and potential epigenetic targets in multiple myeloma. Epigenomics, 6 (2). pp. 215-228. ISSN 1750-1911

Full text not available from this repository.

Abstract

Despite recent advances in therapy, subgroups of multiple myeloma continue to have a poor prognosis. Numerous epigenetic changes have been described and occur as both etiologic and secondary events, making myeloma a good disease in which to understand the role of epigenetic therapies. Here, we describe a number of current and potential epigenetic targets in myeloma.

Item Type:	Review Article
Authors (ICR Faculty only):	Davies, Faith and Morgan, Gareth
All Authors:	Pawlyn, C., Kaiser, M. F., Davies, F. E., Morgan, G. J.
Additional Information:	ISI Document Delivery No.: AG8RC Times Cited: 0 Cited Reference Count: 105 Pawlyn, Charlotte Kaiser, Martin F. Davies, Faith E. Morgan, Gareth J. Myeloma UK The Institute of Cancer Research has a commercial interest in the development of epigenetic therapies. C Pawlyn is a Wellcome Trust Clinical Research Fellow. FE Davies is a CRUK Senior Cancer Fellow. The Centre for Myeloma Research is supported by Myeloma UK. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. 0 FUTURE MEDICINE LTD LONDON EPIGENOMICS-UK
Uncontrolled Keywords:	bromodomain inhibitor chromatin DNA methyltransferase inhibitor histone deacetylase inhibitor histone demethylase inhibitor histone methyltransferase inhibitor multiple myeloma STEM-CELL TRANSPLANTATION HISTONE DEACETYLASE INHIBITOR ADVERSE PROGNOSTIC-FACTOR IN-SITU HYBRIDIZATION MLL-FUSION LEUKEMIA DNA METHYLATION GENE-EXPRESSION PLUS DEXAMETHASONE THERAPEUTIC STRATEGY T(4/14) MYELOMA
Research teams:	ICR divisions > Clinical Studies > Molecular Haematology (including Cytogenetics Group and Cell Markers) ICR divisions > Molecular Pathology > Molecular Haematology (including Cytogenetics Group and Cell Markers) Closed research groups > Myeloma Targeted Treatment
Depositing User:	Barry Jenkins
Date Deposited:	24 Jun 2014 15:35
Last Modified:	13 Nov 2015 16:50
URI:	http://publications.icr.ac.uk/id/eprint/13357

Actions (login required)

View Item